HPV vaccines
Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.
1. A tri-segmented arenavirus viral vector comprising one L segment and two S segments and a nucleotide sequence encoding a polypeptide comprising an amino acid sequence that is at least 99% identical to SEQ ID NO: 10, and wherein one of the two S segments is selected from the group consisting of:
a. an S segment wherein the ORF encoding the NP is under control of an arenavirus 5′ UTR;
b. an S segment wherein the ORF encoding the Z protein is under control of an arenavirus 5′ UTR;
c. an S segment wherein the ORF encoding the L protein is under control of an arenavirus 5′ UTR;
d. an S segment wherein the ORF encoding the GP is under control of an arenavirus 3′ UTR;
e. an S segment wherein the ORF encoding the L protein is under control of an arenavirus 3′ UTR; and
f. an S segment, wherein the ORF encoding the Z protein is under control of an arenavirus 3′ UTR.
2. The tri-segmented arenavirus viral vector of claim 1 , wherein inter-segmental recombination of the two S segments, uniting two arenavirus ORFs on only one instead of two separate segments, abrogates viral promoter activity.
3. The tri-segmented arenavirus viral vector of claim 1 , wherein the arenavirus 3′ UTR is the 3′ UTR of the arenavirus S segment or the arenavirus L segment, and wherein the arenavirus 5′ UTR is the 5′ UTR of the arenavirus S segment or the arenavirus L segment.
4. The tri-segmented arenavirus viral vector of claim 1 , wherein the two S segments each comprise a nucleotide sequence encoding a polypeptide comprising an amino acid sequence that is at least 99% identical to SEQ ID NO: 10.
5. The tri-segmented arenavirus viral vector of claim 1 , wherein the tri-segmented arenavirus viral vector comprises all four arenavirus ORFs, and wherein the tri-segmented arenavirus viral vector is infectious and replication-competent.
6. A tri-segmented arenavirus viral vector comprising one L segment and two S segments, wherein a first S segment is engineered to carry an ORF encoding GP in a position under control of an arenavirus 3′ UTR and an ORF encoding a polypeptide comprising an amino acid sequence that is at least 99% identical to SEQ ID NO: 10 in a position under control of an arenavirus 5′ UTR and a second S segment is engineered to carry an ORF encoding NP in a position under control of an arenavirus 3′ UTR and an ORF encoding a polypeptide comprising an amino acid sequence that is at least 99% identical to SEQ ID NO: 10 in a position under control of an arenavirus 5′ UTR, wherein the arenavirus 3′ UTR is the 3′ UTR of the arenavirus S segment and the arenavirus 5′ UTR is the 5′ UTR of the arenavirus S segment.
7. The tri-segmented arenavirus viral vector of claim 1 , wherein the tri-segmented arenavirus viral vector is attenuated.
8. The tri-segmented arenavirus viral vector of claim 1 , wherein the arenavirus viral vector is derived from LCMV.
9. The tri-segmented arenavirus viral vector of claim 8 , wherein the LCMV is MP strain, Armstrong strain, or Armstrong Clone 13 strain.
10. A host cell comprising the tri-segmented arenavirus viral vector of claim 1 .
11. A vaccine comprising the tri-segmented arenavirus viral vector of claim 1 and a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising the tri-segmented arenavirus viral vector of claim 1 and a pharmaceutically acceptable carrier.
13. A method of treating or preventing a human papillomavirus infection in a patient, wherein said method comprises administering to the patient an arenavirus viral vector of claim 1 .
14. The method of claim 13 , wherein the method results in a reduction of pre-exisiting HPV titer in the patient.
15. The method of claim 13 , wherein the method induces an antigen specific CD8+ T-cell response.
16. The method of claim 13 , wherein the HPV infection is symptomatic.
17. The method of claim 13 , wherein the HPV infection is asymptomatic.
18. The method of claim 13 , wherein the method reduces the severity or frequency of, or prevents manifestations of the HPV infection.
19. The method of claim 18 , wherein the manifestation is selected from the group consisting of: cervical cancer, anal cancer, vulvar cancer, vaginal cancer, penile cancer, HPV-positive oropharyngeal cancer (OSCC), common warts, plantar warts, subungual or periungual warts, genital warts, condylomata acuminata or venereal warts, respiratory papillomatosis, and epidermodysplasia verruciformis.
20. A method of treating or preventing a human papillomavirus infection in a patient, wherein said method comprises administering to the patient a first arenavirus viral vector of claim 1 , and administering to the patient a second arenavirus viral vector of claim 1 .
21. The method of claim 20 , wherein the first arenavirus viral vector and the second arenavirus viral vector are homologous.
22. The method of claim 20 , wherein the first arenavirus viral vector and the second arenavirus viral vector are heterologous.
23. A method of inducing an immune response in a subject wherein said method comprises administering to the patient a first arenavirus viral vector of claim 1 and administering to the patient, after a period of time, a second, different arenavirus viral vector of claim 1 .
24. The method of claim 23 , wherein the first arenavirus viral vector and the second arenavirus viral vector express the same antigen.
25. The tri-segmented arenavirus viral vector of claim 1 , wherein propagation of the tri-segmented arenavirus viral vector does not result in a replication-competent bi-segmented viral vector after 70 days of persistent infection in mice lacking type I interferon receptor, type II interferon receptor and recombination activating gene 1 (RAG1) and having been infected with 10 4 PFU of the tri-segmented arenavirus viral vector.
26. The tri-segmented arenavirus viral vector of claim 25 , wherein the tri-segmented arenavirus viral vector has the same tropism as the bi-segmented arenavirus viral vector.
27. The tri-segmented arenavirus viral vector of claim 1 , wherein one of the two S segments is an S segment wherein the ORF encoding the NP is under control of an arenavirus 5′ UTR.
28. The tri-segmented arenavirus viral vector of claim 1 , wherein one of the two S segments is an S segment wherein the ORF encoding the Z protein is under control of an arenavirus 5′ UTR.
29. The tri-segmented arenavirus viral vector of claim 1 , wherein one of the two S segments is an S segment wherein the ORF encoding the L protein is under control of an arenavirus 5′ UTR.
30. The tri-segmented arenavirus viral vector of claim 1 , wherein one of the two S segments is an S segment wherein the ORF encoding the GP is under control of an arenavirus 3′ UTR.
31. The tri-segmented arenavirus viral vector of claim 1 , wherein one of the two S segments is an S segment wherein the ORF encoding the L protein is under control of an arenavirus 3′ UTR.
32. The tri-segmented arenavirus viral vector of claim 1 , wherein one of the two S segments is an S segment wherein the ORF encoding the Z protein is under control of an arenavirus 3′ UTR.
33. The tri-segmented arenavirus viral vector of claim 1 , wherein one of the two S segments is an S segment wherein the ORF encoding the GP is under control of an arenavirus 3′ UTR, and wherein the arenavirus 3′ UTR is the 3′ UTR of the arenavirus S segment.
34. The tri-segmented arenavirus viral vector of claim 1 , wherein said polypeptide comprise an amino acid sequence that is 100% identical to the amino acid sequence of SEQ ID NO: 10.
35. The tri-segmented arenavirus viral vector of claim 4 , wherein the polypeptide comprises an amino acid sequence that is 100% identical to SEQ ID NO: 10.
36. The tri-segmented arenavirus viral vector of claim 6 , wherein the polypeptides encoded on the first and second S segments comprise amino acid sequences that are 100% identical to SEQ ID NO: 10.
37. A tri-segmented arenavirus viral vector comprising one L segment and two S segments, wherein a first S segment is engineered to carry an ORF encoding GP in a position under control of an arenavirus 5′ UTR and an ORF encoding a polypeptide comprising an amino acid sequence that is at least 99% identical to SEQ ID NO: 10 in a position under control of an arenavirus 3′ UTR and a second S segment is engineered to carry an ORF encoding NP in a position under control of an arenavirus 5′ UTR and an ORF encoding a polypeptide comprising an amino acid sequence that is at least 99% identical to SEQ ID NO: 10 in a position under control of an arenavirus 3′ UTR, wherein the arenavirus 3′ UTR is the 3′ UTR of the arenavirus S segment and the arenavirus 5′ UTR is the 5′ UTR of the arenavirus S segment.
38. The tri-segmented arenavirus viral vector of claim 37 , wherein the polypeptides encoded on the first and second S segments comprise amino acid sequences that are 100% identical to SEQ ID NO: 10.
39. The tri-segmented arenavirus viral vector of claim 6 , wherein the tri-segmented arenavirus viral vector is attenuated.
40. The tri-segmented arenavirus viral vector of claim 6 , wherein the arenavirus viral vector is derived from LCMV.
41. The tri-segmented arenavirus viral vector of claim 40 , wherein the LCMV is MP strain, Armstrong strain, or Armstrong Clone 13 strain.
42. A host cell comprising the tri-segmented arenavirus viral vector of claim 6 .
43. A vaccine comprising the tri-segmented arenavirus viral vector of claim 6 and a pharmaceutically acceptable carrier.
44. A pharmaceutical composition comprising the tri-segmented arenavirus viral vector of claim 6 and a pharmaceutically acceptable carrier.
45. A tri-segmented arenavirus viral vector comprising one L segment and two S segments, wherein a first S segment is engineered to carry an ORF encoding GP in a position under control of an arenavirus 3′ UTR and an ORF encoding a polypeptide consisting of an amino acid sequence that is 100% identical to SEQ ID NO: 10 in a position under control of an arenavirus 5′ UTR and a second S segment is engineered to carry an ORF encoding NP in a position under control of an arenavirus 3′ UTR and an ORF encoding a polypeptide consisting of an amino acid sequence that is 100% identical to SEQ ID NO: 10 in a position under control of an arenavirus 5′ UTR, wherein the arenavirus 3′ UTR is the 3′ UTR of the arenavirus S segment and the arenavirus 5′ UTR is the 5′ UTR of the arenavirus S segment, wherein the tri-segmented arenavirus viral vector is attenuated, and wherein the arenavirus viral vector is derived from LCMV.
46. A host cell comprising the tri-segmented arenavirus viral vector of claim 45 .
47. A vaccine comprising the tri-segmented arenavirus viral vector of claim 45 and a pharmaceutically acceptable carrier.
48. A pharmaceutical composition comprising the tri-segmented arenavirus viral vector of claim 45 and a pharmaceutically acceptable carrier.
49. A tri-segmented arenavirus viral vector comprising one L segment and two S segments, wherein a first S segment is engineered to carry an ORF encoding GP in a position under control of an arenavirus 3′ UTR and an ORF encoding a polypeptide consisting of an amino acid sequence that is 100% identical to SEQ ID NO: 10 in a position under control of an arenavirus 5′ UTR and a second S segment is engineered to carry an ORF encoding NP in a position under control of an arenavirus 3′ UTR and an ORF encoding a polypeptide consisting of an amino acid sequence that is 100% identical to SEQ ID NO: 10 in a position under control of an arenavirus 5′ UTR, wherein the arenavirus 3′ UTR is the 3′ UTR of the arenavirus S segment and the arenavirus 5′ UTR is the 5′ UTR of the arenavirus S segment, wherein the tri-segmented arenavirus viral vector is attenuated, and wherein the arenavirus viral vector is derived from Pichinde virus.
50. A host cell comprising the tri-segmented arenavirus viral vector of claim 49 .
51. A vaccine comprising the tri-segmented arenavirus viral vector of claim 49 and a pharmaceutically acceptable carrier.
52. A pharmaceutical composition comprising the tri-segmented arenavirus viral vector of claim 49 and a pharmaceutically acceptable carrier.